IP Verse

Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma - EP3463457

The patent EP3463457 was granted to Bristol Myers Squibb on Jun 28, 2023. The application was originally filed on Jun 1, 2017 under application number EP17730627A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3463457

BRISTOL MYERS SQUIBB
Application Number
EP17730627A
Filing Date
Jun 1, 2017
Status
Granted And Under Opposition
May 26, 2023
Grant Date
Jun 28, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PAJAROMar 27, 2024BIRD & BIRDADMISSIBLE
STRAWMANMar 22, 2024HOFFMANN EITLEADMISSIBLE

Patent Citations (33) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2012263677
DESCRIPTIONUS2013017199
DESCRIPTIONUS2014341917
DESCRIPTIONUS2014356353
DESCRIPTIONUS2015079109
DESCRIPTIONUS5977318
DESCRIPTIONUS6051227
DESCRIPTIONUS6682736
DESCRIPTIONUS6808710
DESCRIPTIONUS6984720
DESCRIPTIONUS7034121
DESCRIPTIONUS7488802
DESCRIPTIONUS7605238
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8168757
DESCRIPTIONUS8217149
DESCRIPTIONUS8354509
DESCRIPTIONUS8609089
DESCRIPTIONUS8779105
DESCRIPTIONUS8779108
DESCRIPTIONUS8900587
DESCRIPTIONWO2007113648
DESCRIPTIONWO2012122444
DESCRIPTIONWO2012145493
DESCRIPTIONWO2013173223
DESCRIPTIONWO2014179664
DESCRIPTIONWO2014194302
DESCRIPTIONWO2015085847
DESCRIPTIONWO2015112800
DESCRIPTIONWO2015112900
DESCRIPTIONWO2016149201
OPPOSITIONWO2017210453

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- RADHAKRISHNAN RAMCHANDREN ET AL, "Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study", JOURNAL OF CLINICAL ONCOLOGY, US, (20190810), vol. 37, no. 23, doi:10.1200/JCO.19.00315, ISSN 0732-183X, pages 1997 - 2007, XP055675442
OPPOSITION- Anonymous, "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", History of Changes for Study: NCT02335918, (20150107), History of Changes for Study: NCT02335918 , URL: https://clinicaltrials.gov/ct2/history/NCT02335918?A=1&B=17&C=merged#StudyPageTop, XP093181094-
OPPOSITION- Anonymous, "A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)", History of Changes for Study: NCT02713867, (20160426), History of Changes for Study: NCT02713867, URL: ClinicalTrials.gov , XP093181124-
OPPOSITION- Anonymous, "DOXORUBICIN (ADRIAMYCIN, ADRIA, ADR, DOXO)", Patient & Family Education Materials, (20150801), Patient & Family Education Materials, URL: https://www.childrensmn.org/educationmaterials/childrensmn/article/15672/doxorubicin-adriamycin-adria-adr-doxo/, XP093181131-
OPPOSITION- Anonymous, "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors", History of Changes for Study: NCT01968109, (20131018), History of Changes for Study: NCT01968109, URL: https://clinicaltrials.gov/study/NCT01968109?tab=history&a=1&b=1#StudyPageTop, XP093181089-
OPPOSITION- Armand Philippe, Margaret Ann Shipp, John Kuruvilla, Graham P Collins, Rod Ramchandren, John Timmerman, Anne Sumbul, Mary M. Ruisi, Kazunobu Kato, And Stephen Maxted Ansell, "TPS7573: A phase 2 study of a nivolumab (nivo) containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D", American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2016, Chicago, Illinois, USA, American Society of Clinical Oncology, (20160603), pages 1 - 1, XP093179535-
OPPOSITION- Bristol-Myers Squibb, "NCT02181738 Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)", ClinicalTrials.gov, NLM, (20160510), pages 1 - 23, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02181738?tab=history&a=44, XP093179527-
OPPOSITION- Bristol-Myers Squibb, "NCT02181738 Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)", ClinicalTrials.gov, NLM, (20160526), pages 1 - 23, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02181738?tab=history&a=45, XP093179525-
OPPOSITION- Chu, Et Al, "Principles of Cancer Management: Chemotherapy", Cancer: Principles & Practice of Oncology, (20010101), pages 289 - 306, XP055694919-
OPPOSITION- Haniff Haydia, "Brentuximab Vedotin Should Not Be Combined With Bleomycin in First-Line Treatment of Hodgkin Lymphoma", Oncology & Biotech News, MJH Life Sciences, (20131201), vol. 7, no. 12, pages 1 - 6, XP093179519-
OPPOSITION- Nhs, "Lymphoma - Bleomycin-Dacarbazine-Doxorubicin-Vinblastine (ABVD)", Chemotherapy Protocol, Version 1.2, (20150101), pages 1 - 8, XP093180997-
OPPOSITION- Joel Sunshine, Janis M Taube, "PD-1/PD-L1 inhibitors", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS,, NL, NL , (20150801), vol. 23, doi:10.1016/j.coph.2015.05.011, ISSN 1471-4892, pages 32 - 38, XP055304528
OPPOSITION- Younes Anas, Connors Joseph M, Park Steven I, Fanale Michelle, O'meara Megan M, Hunder Naomi N, Huebner Dirk, Ansell Stephen M, "Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20131115), vol. 14, no. 13, doi:10.1016/S1470-2045(13)70501-1, ISSN 1470-2045, pages 1348 - 1356, XP093105263
OPPOSITION- Aaron Goodman, Sandip P. Patel, Razelle Kurzrock, "PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas", NATURE REVIEWS CLINICAL ONCOLOGY, Nature, NY, US, NY, US , (20170401), vol. 14, no. 4, doi:10.1038/nrclinonc.2016.168, ISSN 1759-4774, pages 203 - 220, XP055628484
OPPOSITION- Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C. Scott, Martin Gutierrez, Stephen J. Schuster, Michael M. Millenson, Deepika Cattry, Gordon J. Freeman, Scott J. Rodig, Bjoern Chapuy, Azra H. Ligon, Lili Zhu, Joseph F. Grosso, Su Young Kim, John M. Timmerman, Margaret A. Shipp, Philippe Armand, "PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma", The New England journal of medicine, Massachusetts Medical Society, US, US , (20150122), vol. 372, no. 4, doi:10.1056/NEJMoa1411087, ISSN 0028-4793, pages 311 - 319, XP055239003
OPPOSITION- S. Arulogun; M. Hertzberg; M. K. Gandhi, "Recent treatment advances in Hodgkin lymphoma: a concise review", INTERNAL MEDICINE JOURNAL, BLACKWELL SCIENCE,, AU, AU , (20161215), vol. 46, no. 12, doi:10.1111/imj.13051, ISSN 1444-0903, pages 1364 - 1369, XP072168491
OPPOSITION- Ansell Stephen M., Clinic Mayo, "Nivolumab in the Treatment of Hodgkin Lymphoma", Clinical Cancer Research, Association for Cancer Research, US, US, (20170401), vol. 23, no. 7, doi:10.1158/1078-0432.CCR-16-1387, ISSN 1078-0432, pages 1623 - 1626, XP093179509
OPPOSITION- Boll Boris, Goergen Helen, Behringer Karolin, Br Öckelmann Paul J, Hitz Felicitas, Kerkhoff Andrea, Greil Richard, Von Tresckow Bastian, Eichenauer Dennis A, Ürkle Carolin B, Borchmann Sven, Fuchs Michael, Diehl Volker, Engert Andreas, Borchmann Peter, "Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials", Blood, (20160505), vol. 127, no. 18, pages 2189 - 2192, XP093180999
OPPOSITION- Armand Philippe, "Review Article Immune checkpoint blockade in hematologic malignancies", blood, (20150528), vol. 125, no. 22, doi:10.1182/blood-2015-02-, pages 3393 - 3400, XP093051053
OPPOSITION- Böll Boris; Behringer Karolin; Görgen Helen; Bröckelmann Paul; von Tresckow Bastian; Eichenauer Dennis A.; Fuchs Michael; Diehl Volker; Engert Andreas; Borchmann Peter, "Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials", Blood, American Society of Hematology, US, US , (20141114), vol. 124, no. 21, doi:10.1182/blood.V124.21.3062.3062, ISSN 0006-4971, page 3062, XP086742621
OPPOSITION- Radhakrishnan Ramchandren, Domingo-Domènech Eva, Rueda Antonio, Trněný Marek, Feldman Tatyana A., Lee Hun Ju, Provencio Mariano, Sillaber Christian, Cohen Jonathon B., Savage Kerry J., Willenbacher Wolfgang, Ligon Azra H., Ouyang Jing, Redd Robert, Rodig Scott J., Shipp Margaret A., Sacchi Mariana, Sumbul Anne, Armand Philippe, Ansell Stephen M., "Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study", Journal of Clinical Oncology, Grune & Stratton, (20190810), vol. 37, no. 23, doi:10.1200/JCO.19.00315, ISSN 0732-183X, pages 1997 - 2007, XP055675442
OPPOSITION- Martin William, Ristow Kay, Habermann Thomas, Colgan Joseph, Witzig Thomas, Ansell Stephen, "Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma", Journal of Clinical Oncology, Lippincott Williams & Wilkins, USA, USA , (20051020), vol. 23, no. 30, doi:10.1200/JCO.2005.02.7243, ISSN 1527-7755, pages 7614 - 7620, XP009555237
OPPOSITION- Younes Anas, Santoro Armando, Zinzani Pier Luigi, Timmerman John, Ansell Stephen Maxted, Armand Philippe, Fanale Michelle A., Ratanatharathorn Voravit, Kuruvilla John, Cohen Jonathon Brett, Collins Graham P, Savage Kerry J., Trněný Marek, Kato Kazunobu, Farsaci Benedetto, Parker Susan M., Rodig Scott J., Shipp Margaret Ann, Engert Andreas, "Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.", Journal of Clinical Oncology, Grune & Stratton, (20160520), vol. 34, no. 15_suppl, doi:10.1200/JCO.2016.34.15_suppl.7535, ISSN 0732-183X, pages 7535 - 7535, XP093105013
OPPOSITION- Armand Philippe, Margaret Ann Shipp, John Kuruvilla, Graham P Collins, Rod Ramchandren, John Timmerman, Anne Sumbul, Mary M. Ruisi, Kazunobu Kato, And Stephen Maxted Ansell, "A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.", Journal of Clinical Oncology, Grune & Stratton, (20160520), vol. 34, no. 15, Suppl., doi:10.1200/JCO.2016.34.15_suppl.TPS7573, ISSN 0732-183X, page TPS7573, XP093179513
OPPOSITION- Jose C Villasboas ; Stephen M Ansell, "Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab", EXPERT REVIEW OF ANTICANCER THERAPY, FUTURE DRUGS LTD., UK, UK , (20160101), vol. 16, no. 1, doi:10.1586/14737140.2016.1121812, ISSN 1744-8328, pages 5 - 12, XP008185157
OPPOSITION- Bond David, Alinari Lapo, "Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab", Journal of blood medicine, Taylor & Francis Ltd, New Zealand, New Zealand , (20170511), Volume 8, doi:10.2147/JBM.S117452, ISSN 1179-2736, pages 41 - 54, XP093179511
OPPOSITION- Liu Y L, Liu Y L, Song Y Q, Zhu J, "Research progress on PD-1 inhibitors in lymphoma therapy", Chinese Journal of Hematology, Tianjin, CN, CN , (20160901), vol. 37, no. 9, doi:10.3760/cma.j.issn.0253-2727.2016.09.021, ISSN 0253-2727, pages 829 - 832, XP093179521

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents